In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Micro-Dosing Gene Therapy: A Recipe For Success?

King’s College Spinout AviadoBio Is Targeting FTD And ALS

Executive Summary

Utilizing the genetic overlap between frontotemporal dementia and amyotrophic lateral sclerosis, AviadoBio is seeking to develop gene therapies which can stop both these devastating diseases in their tracks using novel delivery techniques.

You may also be interested in...



FDA Leader: We Need To Remove Surprises From Gene Therapy Development

Embattled gene therapy companies will take comfort from desire of FDA and EMA help smooth the process of bringing the novel treatments to market.

Ex-Novartis Exec Unveils Neurodegeneration Gene Therapy Start-Up AviadoBio

AviadoBio believes it can overcome barriers to making gene therapy work in neurodegenerative diseases, and its new CEO knows what it takes to make a commercial success in the field.

Novartis Steers Zolgensma Towards Commercial Success In Europe

The head of Novartis Gene Therapies in Europe tells Scrip that innovative payment models and involving all stakeholders have helped payers see beyond a simple price tag and see the benefits of a one-time gene therapy for spinal muscular atrophy.

Topics

Latest News
See All
UsernamePublicRestriction

Register

IV125122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel